Sponsors

Lead Sponsor

Neotherix Limited

Collaborators

Lorien Engineering Solutions (a division of GP Strategies Ltd)
Smith & Nephew Advanced Wound Management
NAMSA
Innovate UK

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Is the patient at least 18 years of age
•Is the patient male, or is not pregnant or lactating and is using contraception
•Has the patient been diagnosed with a non-melanoma skin cancer (basal cell carcinoma BCC or squamous cell carcinoma SCC) for which the chosen therapeutic option is surgical excision followed by secondary intention healing
•Is the excisional wound greater than 10mm x 10mm in size and less than or equal to 35mm x 35mm after any attempt at primary closure
•Does the patient have limited skin laxity which would make primary closure of the surgical excision difficult
•Is the patient able to understand the aims and objectives of the trial and are they willing to consent

Exclusion Criteria

•Has the patient been diagnosed with any transmittable viral diseases (HIV, Hepatitis B or C)
•Has the patient been diagnosed with, or is it suspected that they have metastatic disease
•Does the patient have a history of malignant melanoma or any concomitant disease likely to impede wound healing
•Has the patient been diagnosed with pre-existing wound infection
•Is the patient taking any medication known to interfere with skin grafts (i.e. warfarin and other anticoagulants, steroids, NSAIDs and immunosuppressants)
•Has the excised wound been entirely treated by primary closure
•Does the patient have a history of any significant cardiac, pulmonary, renal, hepatic, neurological and/ or immune dysfunction that may affect wound healing
•Does the patient know of any allergy to any of the device materials to be used in the trial
•Does the patient have a known history of poor compliance with medical treatment
•Has the patient participated in this trial previously and healed or been withdrawn
•Is the patient currently participating in any other clinical trial

Related studies

RECRUITINGPhase 2

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

NCT06532279 · Clinical Stage I HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, Clinical Stage II HPV-Mediated (p16-Positive) Oropharyngeal Carcinoma AJCC v8, and more

RECRUITINGPhase 2

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

NCT07088211 · Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma

RECRUITINGPhase 1/2

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

NCT05639972 · HPV-Associated Cervical Carcinoma, HPV-Related Carcinoma, and more

RECRUITINGPhase 1

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

NCT05076760 · Solid Tumor, Advanced Cancer, and more

RECRUITING

Patients With Human Papillomavirus-associated Head and Neck Cancer for the Discovery of Predictive Biomarkers to Guide Clinical Intervention

NCT06821243 · Squamous Cell Carcinoma of Oropharynx

View all related studies →

EktoTherix™ Regenerative Tissue Scaffold for Repair of Surgical Excision Wounds

What this study is about

Save this trial guide to your notes

Sponsors

Related studies

Testing the Addition of the Drug BMX-001, a Radioprotector, or a Placebo to the Usual Chemoradiation Therapy for Patients With Head and Neck Cancer

Sacituzumab Tirumotecan and Toripalimab in the First-line Treatment of HNSCC

E7 T-cell Receptor (TCR) -T Cell Induction Therapy for Locoregionally Advanced HPV-associated Cancers

MEM-288 Oncolytic Virus Alone and in Combination With Standard of Care Therapy in Advanced Solid Tumors

Patients With Human Papillomavirus-associated Head and Neck Cancer for the Discovery of Predictive Biomarkers to Guide Clinical Intervention

Trial snapshot

Condition

Locations shown

For caregivers